Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBT: 2011-2025

Historic EBT for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to -$83.5 million.

  • Enanta Pharmaceuticals' EBT rose 36.04% to -$18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.5 million, marking a year-over-year increase of 29.07%. This contributed to the annual value of -$83.5 million for FY2025, which is 29.07% up from last year.
  • Enanta Pharmaceuticals' EBT amounted to -$83.5 million in FY2025, which was up 29.07% from -$117.8 million recorded in FY2024.
  • Enanta Pharmaceuticals' 5-year EBT high stood at -$83.5 million for FY2025, and its period low was -$131.0 million during FY2023.
  • For the 3-year period, Enanta Pharmaceuticals' EBT averaged around -$110.8 million, with its median value being -$117.8 million (2024).
  • Per our database at Business Quant, Enanta Pharmaceuticals' EBT crashed by 207.20% in 2021 and then climbed by 29.07% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' EBT (Yearly) stood at -$107.6 million in 2021, then fell by 13.58% to -$122.2 million in 2022, then dropped by 7.21% to -$131.0 million in 2023, then rose by 10.08% to -$117.8 million in 2024, then climbed by 29.07% to -$83.5 million in 2025.